Page 430 - شرور شركات الأدوية

‫ﴍور ﴍﻛﺎت اﻷدوﻳﺔ‬

(54) Soyk, C., B. Pfefferkorn, P. McBride, and R. Rieselbach. 2010. Med-
ical student exposure to and attitudes about pharmaceutical companies.
World Medical Journal 109: 142–148.

(55) Fischer MA, Keough ME, Baril JL, Saccoccio L, Mazor KM, Ladd
E, et al. Prescribers and Pharmaceutical Representatives: Why Are We Still
Meeting? J Gen Intern Med. 2009 Jul;24(7):795–801.

(56) Morgan MA, Dana J, Loewenstein G, Zinberg S, Schulkin J. Inter-
actions of doctors with the pharmaceutical industry. J Med Ethics. 2006
Oct;32(10):559–63.

(57) B Hodges, ‘Interactions with the pharmaceutical industry: expe-
riences and attitudes of psychiatry residents, interns and clerks,’ CMAJ:
Canadian Medical Association Journal = Journal De l’Association Medicale
Canadienne 153, no. 5 (September 1,1995): 553–559.

(58) Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J,
Othman N, et al. Information from Pharmaceutical Companies and the
Quality, Quantity, and Cost of Physicians’ Prescribing: A Systematic Re-
view. PLoS Med. 2010 Oct 19;7(10):e1000352.

(59) MM Chren and CS Landefeld, ‘Physicians’ behavior and their in-
teractions with drug companies. A controlled study of physicians who re-
quested additions to a hospital drug formulary,’ JAMA: The Journal of the
American Medical Association 271, no. 9 (March 2, 1994): 684–689.

(60) Ladd EC, Mahoney DF, Emani S. ‘Under the radar’: nurse practi-
tioner prescribers and pharmaceutical industry promotions. Am J Manag
Care. 2010;16(12):e358–362.

(61) Zipkin DA, Steinman MA. Interactions Between Pharmaceuti-
cal Representatives and Doctors in Training. J Gen Intern Med. 2005
Aug;20(8):777–86.

430